AI in Pharmacovigilance: Systems, Agents & Governance · Section 13.13
~5 min read · The Drug Safety Coach — Global PV Career Course
Key points
Full text
It’s possible to understand agentic AI, CIOMS WG XIV, and the EU AI Act’s risk classifications thoroughly and still not have a clear picture of what changes in a normal shift once AI tools are actually live in a case processor’s workflow. This lesson closes that gap directly, module by module task.
At intake, NLP does the first pass on unstructured input — an email, a scanned form, a call transcript — extracting candidate patient, drug, and event information into structured fields, and flagging likely duplicates by comparing narrative similarity against existing cases. The processor’s job shifts from typing everything from scratch to verifying and correcting what the model extracted, which is faster but requires just as much attention, arguably more, since an unverified extraction error is invisible until it causes a downstream problem.
At coding, an AI model suggests a MedDRA term from the verbatim text, but the processor still owns the final term selection — confidence scores here matter operationally: a low-confidence suggestion should get closer scrutiny, not less, precisely because the model itself is signalling uncertainty. At narrative and PBRER-summary drafting, GenAI produces a first draft from structured case data, which a medical reviewer or writer then edits and approves — the mandatory physician review before submission covered in the AI-in-PV glossary terms isn’t a formality, it’s the actual point where clinical judgment re-enters a process that started as a machine draft.
The common thread across every one of these touchpoints is that sign-off has to be real, not nominal. A named, trained person actually reviewing the AI output for that specific case — checking a suggested code against the verbatim, reading a drafted narrative against the source documents, confirming a flagged duplicate is genuinely a duplicate — is what Human-in-the-Loop means in daily practice. A workflow where AI output is technically "reviewed" by someone clicking approve without actually checking it isn’t HITL in any sense that would survive an inspection, and it defeats the entire purpose of the human-oversight requirement covered earlier in this module.
Important
This lesson is deliberately practical rather than conceptual. Module 13’s earlier lessons covered the AI taxonomy, governance frameworks, and the HITL principle itself — this one asks a narrower, more useful question: on an ordinary Tuesday, processing an ordinary case, what does having AI in the workflow actually change about what you personally do?
Quick check
Test yourself before moving on — no pressure, just click an answer.
1. What does genuine Human-in-the-Loop (HITL) review look like in daily case processing, as opposed to a nominal version of it?